公开(公告)号：US20190365766A1

公开(公告)日：2019-12-05

申请号：US16540248

申请日：2019-08-14

申请人： Celgene Corporation

发明人： Stacie S. CANAN ,  Natalie Anne HAWRYLUK

IPC分类号： A61K31/52 ,  C07C211/36 ,  C07D473/32

摘要： Provided herein are Purine Compounds of Formula (I) or pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of a Purine Compound, and methods for treating or preventing malaria comprising the administration of an effective amount of a Purine Compound.

公开(公告)号：US20170348315A1

公开(公告)日：2017-12-07

申请号：US15611061

申请日：2017-06-01

申请人： Celgene Corporation

发明人： Stacie S. CANAN ,  Natalie Anne HAWRYLUK ,  Michael John WITTY

IPC分类号： A61K31/52 ,  C07C211/36 ,  C07C211/57 ,  C07D413/02 ,  C07D473/32 ,  C07C217/02 ,  C07C13/10 ,  C07C13/06 ,  G01N33/569

CPC分类号： A61K31/52 ,  A61K45/06 ,  C07C13/06 ,  C07C13/10 ,  C07C211/36 ,  C07C211/57 ,  C07C217/02 ,  C07D413/02 ,  C07D473/32 ,  G01N33/56905

摘要： Provided herein are Aminopurine compounds of Formula I: or pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing animal and human protozoal infections.

公开(公告)号：US20200330469A1

公开(公告)日：2020-10-22

申请号：US16920752

申请日：2020-07-06

申请人： Celgene Corporation

发明人： Stacie S. CANAN ,  Natalie Anne HAWRYLUK

IPC分类号： A61K31/52 ,  C07C211/36 ,  C07D473/32

摘要： Provided herein are Purine Compounds of Formula (I) or pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of a Purine Compound, and methods for treating or preventing malaria comprising the administration of an effective amount of a Purine Compound.

公开(公告)号：US20180280399A1

公开(公告)日：2018-10-04

申请号：US16000969

申请日：2018-06-06

申请人： Celgene Corporation

发明人： Stacie S. CANAN ,  Natalie Anne HAWRYLUK ,  Michael John WITTY

IPC分类号： A61K31/52 ,  C07C211/36 ,  C07C211/57 ,  C07D413/02 ,  C07D473/32

CPC分类号： A61K31/52 ,  A61K45/06 ,  C07C13/06 ,  C07C13/10 ,  C07C211/36 ,  C07C211/57 ,  C07C217/02 ,  C07D413/02 ,  C07D473/32 ,  G01N33/56905

摘要： Provided herein are Aminopurine compounds of Formula I: or pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing animal and human protozoal infections.

公开(公告)号：US20180280398A1

公开(公告)日：2018-10-04

申请号：US16000968

申请日：2018-06-06

申请人： Celgene Corporation

发明人： Stacie S. CANAN ,  Natalie Anne HAWRYLUK

IPC分类号： A61K31/52 ,  C07C211/36 ,  C07D473/32 ,  C07C217/02 ,  C07C13/06 ,  G01N33/569 ,  C07D231/02

CPC分类号： A61K31/52 ,  C07C13/06 ,  C07C211/36 ,  C07C217/02 ,  C07D231/02 ,  C07D473/32 ,  G01N33/56905 ,  Y02A50/411

摘要： Provided herein are Purine Compounds of Formula (I) or pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of a Purine Compound, and methods for treating or preventing malaria comprising the administration of an effective amount of a Purine Compound.

公开(公告)号：US20170348316A1

公开(公告)日：2017-12-07

申请号：US15611108

申请日：2017-06-01

申请人： Celgene Corporation

发明人： Stacie S. CANAN ,  Natalie Anne HAWRYLUK

IPC分类号： A61K31/52 ,  C07D473/32 ,  C07C211/36 ,  C07D231/02 ,  C07C13/06 ,  G01N33/569 ,  C07C217/02

CPC分类号： A61K31/52 ,  C07C13/06 ,  C07C211/36 ,  C07C217/02 ,  C07D231/02 ,  C07D473/32 ,  G01N33/56905

摘要： Provided herein are Purine Comounds of Formula (I) or pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of a Purine Compound, and methods for treating or preventing malaria comprising the administration of an effective amount of a Purine Compound.